

A Phase 1, Randomized, Double-Blind, Two-Arm, Placebo-Controlled, Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of LJPC-401 in Healthy Adults

ACTRN12617000689370

Status COMPLETED
Sponsor La Jolla Pharmaceutical Australia Pty Ltd, an affiliate of La Jolla Pharmaceutical Company
Enrollment 36 participants

Key Eligibility Criteria

Inclusion (1)

- Healthy volunteers, negative drug and alcohol tests, BMI 18-32 inclusive

Exclusion (1)

- Blood pressure less than 90/60 or greater than 160/100, limited alcohol and tobacco use, infection or other serious underlying medical condition

Locations (1 total)

WA, Australia